UK anticoagulants market is estimated to grow at a CAGR of 7.0% during the forecast period. Significant incidences of atrial fibrillation and myocardial infarction are one of the major factors accelerating market growth. As per the British Heart Federation (BHF), in 2018, nearly 1.4 million people in the country have been diagnosed with atrial fibrillation (AF). Further, over 100,000 hospital admissions annually are reported due to heart attacks, which represent 280 admissions every day. Over 200,000 UK hospital visits annually are reported due to heart attack.
A full report of UK Anticoagulants Market is available at: https://www.omrglobal.com/industry-reports/uk-anticoagulants-market
This, in turn, is contributing to the rising demand for anticoagulants in the country that are used for the treatment and prevention of blood clots that may occur in the blood vessels. Blood clots can block blood vessels (a vein or an artery). A blocked artery inhibits oxygen and blood from getting to a part of the body (for instance, to a part of the lungs, heart, or brain). This, in turn, may cause severe problems including a heart attack or stroke. A blood clot in a large vein, including a deep vein thrombosis (DVT), can cause severe problems. Therefore, anticoagulants are utilized for the prevention of blood clots and atrial fibrillation (AF) is the most common condition in which blood clots are formed.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/uk-anticoagulants-market
Scope of the UK Anticoagulants Market
Market Coverage
- Market number available for 2019-2026
- Base year- 2019
- Forecast period- 2020-2026
- Segment Covered- By Type and Application
- Competitive Landscape- AstraZeneca Plc, Bristol Myers Squibb Co., Pfizer Inc., Daiichi Sankyo Co. Ltd., and Boehringer Ingelheim GmbH
Recent Strategic Initiatives in the UK Anticoagulants Market
- In July 2020, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended a generic version of apixaban, an anticoagulant medicine. In the meantime, the US FDA approved a generic version of chlorzoxazone, a muscle relaxant. Apixaban is an anticoagulant that is used for the treatment and prevention of blood clots and prevention of stroke. In 2011, it was first approved for use in the EU and is sold with the brand name Eliquis by Pfizer/Bristol-Myers Squibb.
- In November 2020, Boehringer Ingelheim declared the European Medicines Agency’s (EMA) Committee has adopted a positive opinion for Pradaxa (dabigatran etexilate) to treat venous thromboembolic events (VTE) and prevention of recurrent VTE in pediatric patients from birth to less than 18 years of age.
Key questions addressed by the report
- What is the market growth rate?
- Which segment dominates the market in the base year?
- Which segment will project the fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from the pre-COVID forecast
o Most affected segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
UK Anticoagulants Market-Segmentation
By Type
- Novel Oral Anticoagulants (NOACs)
- Vitamin K Antagonist
- Heparin and Low Molecular Weight Heparin (LMWH)
By Application
- Pulmonary Embolism
- Atrial Fibrillation/Myocardial Infarction (Heart Attack)
- Deep Vein Thrombosis (DVT)
- Others
This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.
